Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

PMID:
27325891
2.

IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.

Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K.

Sci Rep. 2016 Jun 10;6:27569. doi: 10.1038/srep27569.

3.
4.

Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics.

Taskesen E, Huisman SM, Mahfouz A, Krijthe JH, de Ridder J, van de Stolpe A, van den Akker E, Verheagh W, Reinders MJ.

Sci Rep. 2016 Apr 25;6:24949. doi: 10.1038/srep24949.

5.

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.

Emadi A, Bade NA, Stevenson B, Singh Z.

Pharmaceuticals (Basel). 2016 Mar 10;9(1). pii: E12. doi: 10.3390/ph9010012.

6.

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.

Voelxen NF, Walenta S, Proescholdt M, Dettmer K, Pusch S, Mueller-Klieser W.

Front Oncol. 2016 Mar 7;6:46. doi: 10.3389/fonc.2016.00046. eCollection 2016.

7.

Acute Myeloid Leukemia: A Concise Review.

Saultz JN, Garzon R.

J Clin Med. 2016 Mar 5;5(3). pii: E33. doi: 10.3390/jcm5030033. Review.

8.

Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Pastore F, Levine RL.

Haematologica. 2016 Mar;101(3):269-78. doi: 10.3324/haematol.2015.140822. Review.

9.

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.

Clark O, Yen K, Mellinghoff IK.

Clin Cancer Res. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27.

PMID:
26819452
10.

The Emerging Hallmarks of Cancer Metabolism.

Pavlova NN, Thompson CB.

Cell Metab. 2016 Jan 12;23(1):27-47. doi: 10.1016/j.cmet.2015.12.006. Review.

PMID:
26771115
11.

Emerging therapeutic drugs for AML.

Stein EM, Tallman MS.

Blood. 2016 Jan 7;127(1):71-8. doi: 10.1182/blood-2015-07-604538. Epub 2015 Dec 10. Review.

PMID:
26660428
12.

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients.

Wang JH, Guo Q, Ma ZX, Ma QL, Yu MX, Yin XF, Lu SS, Xie HQ, Jiang YH, Shen D, Ma LY, Shi H, Yu WJ, Lou YJ, Li Y, Yang M, Xu GX, Mao LP, Li JH, Wang HP, Wang DM, Wei JY, Tong HY, Huang J, Jin J.

PLoS One. 2015 Oct 14;10(10):e0140622. doi: 10.1371/journal.pone.0140622. eCollection 2015.

13.

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V.

J Mol Diagn. 2015 Nov;17(6):661-8. doi: 10.1016/j.jmoldx.2015.06.004. Epub 2015 Aug 30.

PMID:
26331834
14.

Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia.

Wang BH, Li YH, Yu L.

Chin Med J (Engl). 2015 Sep 5;128(17):2395-403. doi: 10.4103/0366-6999.163400. Review.

15.

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.

Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC.

Blood. 2015 Oct 8;126(15):1741-52. doi: 10.1182/blood-2015-05-644591. Epub 2015 Aug 12.

PMID:
26268241
16.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

PMID:
26245674
17.

Molecular Genetic Markers in Acute Myeloid Leukemia.

Yohe S.

J Clin Med. 2015 Mar 12;4(3):460-78. doi: 10.3390/jcm4030460. Review.

18.

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H.

Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Review.

PMID:
26188014
19.

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.

Gallipoli P, Giotopoulos G, Huntly BJ.

Ther Adv Hematol. 2015 Jun;6(3):103-19. doi: 10.1177/2040620715577614. Review.

20.

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.

DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H.

Am J Hematol. 2015 Aug;90(8):732-6. doi: 10.1002/ajh.24072.

Items per page

Supplemental Content

Write to the Help Desk